

SUBJECT INDEX

A

Abdel-Latif, A. A., 86
Acetaminophen
cytochrome P-450 enzymes and, 250
hepatotoxicity of, 170
toxic metabolites of, 12
Acetanilide
metabolism and distribution of, 5
2-Acetylaminofluorene
embryonic bioactivation of, 176
embryotoxic effects of, 180
teratogenicity of, 169-70
Acetylcholine
coexistence with vasoactive intestinal peptide, 95
ganglionic norepinephrine and, 16
leukotrienes and, 126
Acquired immune deficiency syndrome
azidothymidine and, 111
dialyzable leukocyte extract therapy and, 502
Acrolein
embryotoxic effects of, 180
ACTH
hypersecretion of
reserpine and, 17
release of
benzodiazepines and, 309
Acyclovir
herpes simplex virus and, 111
Acyl-CoA:dihydroxyacetone phosphate acyltransferase
hepatic peroxisome proliferation and, 148
Addiction
cocaine, 520
psychopharmacology of, 520-22
Ader, J.-L., 354
Adipate ester plasticizers
hepatic peroxisome proliferation and, 147
Adipocytes
phospholipase C activation in, 91
Adrenal gland
benzodiazepine receptors in, 308-9
 α_1 -Adrenergic receptors
inositol phospholipid metabolism and, 85-87

Adriamycin
teratogenicity of, 175
Adult respiratory distress syndrome
leukotrienes and, 123
Aflatoxin
teratogenicity of, 175
Air pollutants
indoor
toxic effects of, 419-20
toxicology strategies for, 416-22
Air pollution
indoor, 415-16
causative agents of, 427-29
Airway smooth muscle
leukotrienes and, 125-27
Akhtar, R. A., 86
Albertini, R. J., 199
Aldosterone
production of
diazepam and, 309
synthesis and release of
atriopeptin and, 25, 38-39
Aldrin epoxidation
cytochrome P-450 enzymes and, 247
Alkanes
hepatic peroxisome proliferation and, 147
Alkanols
nail penetration by, 64
Allergic rhinitis
leukotrienes and, 134
Allison, J. H., 96
Alopecia totalis
dialyzable leukocyte extract therapy and, 495
glucocorticoids and, 66
Altmeyer, P., 59
Alzheimer's disease
dialyzable leukocyte extract therapy and, 497-98
glutamate receptors and, 457-58
glutamate transport in, 389
N-methyl-D-aspartate receptors and, 89
Ames, B. N., 196
4-Aminobiphenyl
environmental tobacco smoke and, 426
2-Amino-4-phosphonobutyrate receptors, 377-79
Aminophosphonobutyric acid
long-term potentiation of synaptic transmission and, 89
2-Amino-5-phosphonovalerate
excitatory amino acids and, 88
Aminopyrine
hepatic demethylation of, 9
metabolism and distribution of, 5
Amphetamine
hepatic enzyme system and, 9-10
Amyotrophic lateral sclerosis
dialyzable leukocyte extract therapy and, 498
Anderson, K. A., 388
Androgens
conversion to estrogens, 253
teratogenicity of, 166
Androstenedione
cytochrome P-450 enzymes and, 247
Angiotensin
exogenous
atriopeptin and, 26
phosphoinositide hydrolysis and, 89
Angiotensin II
atriopeptin-induced natriuresis and, 36
plasma atriopeptin levels and, 31
Aniline
cytochrome P-450 enzymes and, 250
Anisoylated plasminogen-streptokinase activator complex
pharmacology of, 331-32
Anthralin
psoriasis and, 62
skin disease and, 59
Antiarrhythmics
bile acid-binding resins and, 271
Antibacterials
skin disease and, 59
Antibiotics
skin disease and, 59
Anticholinergics
skin disease and, 59
Anticoagulants
bile acid-binding resins and, 271
teratogenicity of, 166
Anticonvulsants
teratogenicity of, 166
Antidepressants
inositol lipid metabolism and, 83

Antifungals
 nail penetration by, 64
 penetration enhancers and, 60-61
 skin disease and, 59
 tinea capitis and, 66

Antihistamines
 teratogenicity of, 175

Antihypertensives
 bile acid-binding resins and, 271
 nicotinic acid and, 275

Antiparasitics
 skin disease and, 59

Antipyrine
 metabolism and distribution of, 5

Antiseptics
 skin disease and, 59

Antivirals, 111-20
 design of, 112-16
 problems in, 116-19
 prospects for, 119-20

Anxiety
 N-methyl-D-aspartate receptors and, 454-55

Apronitin
 proatriopeptin-processing enzyme and, 33

Arachidonic acid
 leukotrienes and, 123-24
 phospholipase A₂ and, 123
 second messengers and, 74

Arbeit, L. A., 354

Arousal
 N-methyl-D-aspartate receptors and, 453

Arteriosclerotic cardiovascular disease
 dyslipidemias and, 265

Ascher, P., 370, 372

Ascorbate
 embryonic defense and, 181-82

Ashby, R., 179

Aspartate
 2-amino-5-phosphonovalerate and, 88
 phosphoinositide breakdown and, 87

Asthma
 leukotrienes and, 123
 slow-reacting substance of anaphylaxis and, 133

Astrocytes
 glutamate-binding sites on, 388

Atabrine
 tissue distribution of
 dosing regimens and, 4

Atenolol
 atriopeptin release and, 31

Atrial fibrillation
 nicotinic acid and, 275

Atrial natriuretic factor, 23

Atrial natriuretic peptide, 23

Atrial peptides, 23-45

Atrial stretch receptors
 heart rate modulation and, 31

Atriopeptin
 biological activity of
 suppression of, 25
 biosynthesis and storage of, 26-28
 brain and, 26
 cardiac biosynthesis of, 23-24
 cardiovascular effects of, 37-38
 central nervous system and, 39-42
 developmental regulation of, 30
 expression in cardiac ventricle, 42-44
 gene structure and organization of, 28-29
 hormonal interactions of, 38-39
 metabolism of, 33-34
 receptors for, 25, 34-35
 regulatory sequences of, 29-30
 release of, 24-25, 30-33
 renal actions of, 36-37

Atropine
 atriopeptin secretion and, 31
 metabolism and distribution of, 5
 muscarinic cholinergic receptors and, 83
 side effects of, 136

Austen, K. F., 134

Autism
 dialyzable leukocyte extract therapy and, 497-98

Axelrod, J., 4, 5, 9, 10

Azarnoff, D. L., 147

Azidothymidine
 acquired immune deficiency syndrome and, 111

B

Bainbridge reflex
 atrial stretch receptors and, 31

Baldini, W., 85

Bang, N. U., 323

Batrachotoxin
 inositol phosphate release and, 92

Batty, I., 97

Beaune, P., 248, 251

Becker, B. A., 167

Becker, C. M., 156

Behcet's syndrome
 dialyzable leukocyte extract therapy and, 493-95

Benzamidine
 proatriopeptin-processing enzyme and, 33

Benz(a)pyrene
 embryonic bioactivation of, 176
 environmental tobacco smoke and, 426
 teratogenicity of, 175

Benzodiazepine receptors
 peripheral, 307-18
 localization and regulation of, 308-11
 mitochondria and, 311
 molecular properties of, 315-18
 porphyrins and, 312-13

Benzodiazepines
 anxiolytic action of, 16
 peripheral
 biological effects of, 313-15

Benzoyl benzoate
 skin disease and, 59

Benzoyl peroxide
 skin disease and, 59

Benzphetamine
 N-demethylation
 cytochrome P-450 enzymes and, 247

Berliner, R., 4, 5

Bernard, W., 146

Berridge, M. J., 78, 80, 81, 96

Betamethasone dipropionate
 vehicles for, 56

Bisgaard, H., 134, 135

Blaine, E. H., 23

Blanke, H., 324

Blumgart, H. L., 324

Bombesin
 phosphoinositide hydrolysis and, 89

Bonner, T. I., 83

Bradykinin
 phosphoinositide hydrolysis and, 89

Brain
 atriopeptin and, 26
 benzodiazepine receptors in, 308-11

Brain peptides, 521-22

Braun, A. G., 172, 174

Bretlyium
 heart norepinephrine content and, 14

Brewer, G., 385

Bridges, R. J., 365

Brodie, B. B., 1-18

Brodie, S., 2, 8

Bromobenzene
toxic metabolites of, 12

Bronchitis
chronic
leukotrienes and, 123

Bronchoconstriction
leukotrienes and, 133-34

Bronfman, M., 156

Brown, D. A., 89

Brown, L. P., 177

Buckner, C., 127

Bukowski, R. M., 497

Burch, G. E., 64

Burns, J., 4

C

Caffeine
teratogenicity of, 175

Calcium
intracellular
atriopeptin release and, 32

release of
inositol phosphates and, 77-79

Calcium channel agonist BAY k8644
atriopeptin release and, 32

Calcium ionophore A23187
atriopeptin release and, 32

Calcium-mobilizing receptors
phosphoinositide response
and, 92-94

Campbell, J. B., 407

Cancer chemotherapeutic agents
teratogenicity of, 166

Candidiasis
dialyzable leukocyte extract
therapy and, 489-90

Carbamazepine
anticonvulsant actions of
benzodiazepine receptors
and, 311

Carbon tetrachloride
hepatotoxicity of
phenobarbital and, 12

Carcinogenesis
cytochrome P-450 enzymes
and, 245

Cardiac arrhythmias
nicotinic acid and, 275

probucol and, 273

Cardiac ventricle
atriopeptin expression in, 42-44

Cardionatriin, 23

Cardiovascular disease
arteriosclerotic
dyslipidemias and, 265

Cardiovascular system
atriopeptin and, 37-38

Carnitine acetyltransferase
hepatic peroxisome proliferation and, 148

Carnitine octanoyltransferase
hepatic peroxisome proliferation and, 148

β -Carotene
embryonic defense and, 181-82

Catalase
embryonic defense and, 181-82
hepatic peroxisomes and, 146

Cataracts
lovastatin and, 279

Catecholamines
depletion of
reserpine syndrome and, 13

thermoregulation and, 17

Central nervous system
atriopeptin secretion and, 32

neuronal projections in
chemical coding of, 293

Chemical genotoxicity, 189-204

Chemical teratogenesis, 165-82

Chen, S. T., 253, 254, 409

Chloramphenicol acetyltransferase
atriopeptin gene and, 29

Chlorhexadine
skin disease and, 59

Chloroquine
phosphoinositide breakdown
and, 91

Choi, D. W., 386

Cholecytokinin
phosphoinositid hydrolysis
and, 89

Cholesterol
primary dyslipidemias and, 265

Cholestyramine
primary dyslipidemias and, 268-70

Chromosome mutation, 200-3

Chronic discoid lupus erythematosus
dialyzable leukocyte extract
therapy and, 495-96

Chronic familial mucocutaneous candidiasis
dialyzable leukocyte extract
therapy and, 489-90

Chronic hyperfattyability-cognitive dysfunction syndrome
dialyzable leukocyte extract
therapy and, 498-99

Chuang, D.-M., 71, 84, 93, 95

Ciprofibrate
hepatic peroxisome proliferation and, 149

Claxton, L. D., 420

Clayman, M. D., 323

Clofibrate
hepatic peroxisome proliferation and, 148, 149, 151

primary dyslipidemias and, 273

Clonazepam
binding sites of, 308

Coal tar
skin disease and, 59

Cocaine addiction, 520

Colestipol
primary dyslipidemias and, 268

Collen, D., 332, 333

Congestive heart failure
atriopeptin and, 37, 44

Conn, P. J., 82

Convulsions
benzodiazepines and, 314

N-methyl-D-aspartate receptors and, 454

Coproporphyrin
benzodiazepine receptors and, 313

Contisol
cytochrome P-450 enzymes and, 247

Costa, E., 1, 88

Costa, M., 289, 292

Cotinine
detection of, 425-26

Cotman, C. W., 365

Creutzfeld-Jacob disease
dialyzable leukocyte extract
therapy and, 498

Crews, F. T., 91

Critchley, M., 407

Crouch, M. F., 91

Cryptosporidia
dialyzable leukocyte extract
therapy and, 502

Curtis, D. R., 367, 386

Cutaneous leishmaniasis
dialyzable leukocyte extract
therapy and, 492-93

Cyclic nucleotides
kinin responses and, 352

Cyclophosphamide
teratogenicity of, 167-69

Cyclosporin hydroxylation
cytochrome P-450 enzymes and, 247

Cystic fibrosis
leukotrienes and, 123

Cytochrome P-450 enzymes, 241-56

Cytochrome P-452
induction of, 149-50

D

Daly, J. W., 92
 Danysz, W., 441
 Davidson, A. B., 134
 Dawson, A. P., 78
 de Duve, C., 146
 DEHP
 hepatic peroxisome proliferation and, 149
 hepatomegaly and, 150
 Dehydroepiandrosterone 3-sulfate
 cytochrome P-450 enzymes and, 247
 Deltamethrin
 convulsions and, 314
 Dementia
 multiple infarct, 411
 Depression
 desmethylimipramine and, 13
 Desipramine
 cortical serotonin receptor response and, 83
 Desmethylimipramine
 depression and, 13
 Deuteroporphyrin IX
 benzodiazepine receptors and, 313
 DeWood, M. A., 324
 Dexamethasone
 atriopeptin gene expression and, 29
 Diabetes mellitus
 kallikrein-kinin system and, 355-56
 lipoprotein abnormalities and, 266
 Diacylglycerol
 generation of, 72-76
 mode of action of, 76-79
 protein kinase C and, 32, 76-77
 generation of, 72-76
 Dialyzable leukocyte extract, 477-78
 antigen-specific responses to, 485-86
 choice of donor for, 480-81
 clinical response to
 laboratory monitoring of, 485
 fungal diseases and, 489-90
 immunotherapy with, 479-89
 interactive T cells and, 486-87
 in vitro effects of, 487-89
 malignant diseases and, 496-97
 mycobacterial diseases and, 490-92
 neurologic diseases and, 497-99

parasitic infections and, 492-93
 potency of
 in vitro determination of, 483-85
 preparation of, 481-83
 side effects of, 479-80
 therapeutic failures with, 499
 viral infections and, 493-96

Diazepam
 binding sites of, 307-8
 1,1-Dichloroethane
 carcinogenicity of, 433
 Dichloroflavan
 picornavirus uncoating and, 113
 Dicumarol
 duration of action of
 plasma protein binding and, 11
 metabolism and distribution of, 5
 Diethylstilbestrol
 embryonic bioactivation of, 176
 teratogenicity of, 166, 175
 Digitalis
 bile acid-binding resins and, 271
 1,4-Dihydropyridines
 cytochrome P-450 enzymes and, 247
 5,7-Dihydroxytryptamine
 cortical serotonin receptor response and, 83
 Dillon-Carter, O., 93
 Dimethylacetamide
 percutaneous drug penetration and, 62
 Dimethylsulfoxide
 percutaneous drug penetration and, 62
 Disopropyl fluorophosphate
 proatriopeptin-processing enzyme and, 33
 Disoxaril
 picornavirus uncoating and, 113-14
 Diuretics
 bile acid-binding resins and, 271
 thiazide
 secondary dyslipidemias and, 266
 DNA
 chemicals damaging, 190-96
 Docosahexaenoic acid
 dyslipidemias and, 281-82
 Dopamine
 depletion of
 reserpine syndrome and, 13
 kallikrein gene expression and, 348

Drazen, J. M., 134
 Drinking behavior
 atriopeptin and, 42
 Drug-metabolizing enzyme system
 neonates and, 10
 smooth endoplasmic reticulum and, 9
 Drug problem, 518-19
 Drugs
 elimination of
 genetic variation in, 10-11
 embryonic bioactivation of, 175-78
 metabolism and disposition of, 8-12
 metabolites of
 clinical utility of, 11
 percutaneous absorption of, 55-66
 drug vehicles and, 55-59
 nails and, 64-65
 penetration enhancers and, 59-61
 regional differences in, 65-66
 stratum corneum and, 61-63
 sports performance and, 517-18
 tissue distribution of
 dosing regimens and, 4-5
 topical
 penetration enhancers and, 59-61
 Drummond, A. H., 96
 Duckert, F., 330
 Dujovne, C. A., 265
 Dumas, K. J., 59
 Dysbetaipoproteinemia
 arteriosclerotic cardiovascular disease and, 266
 Dyslipidemias, 265-84
 agents affecting, 280-82
 combined drug therapy for, 282-83
 primary, 265-66
 drugs for, 268-80
 secondary, 266

E

Eacho, P. I., 155
 Eatough, D. J., 424
 Econazole
 nail penetration by, 64
 Eicosapentaenoic acid
 dyslipidemias and, 281-82
 Elcombe, C. R., 145
 Embolic stroke, 410-11
 Embryo
 drug bioactivation in, 175-78

reactive metabolites and, 178-82

β -Endorphin, 521

Endozepine benzodiazepine receptors and, 312

Enkephalins, 521

Enteroviruses serotypes of, 113

Ephedrine hepatic enzyme system and, 9-10
inositol phosphate release and, 85

Epidermal dysplasia dialyzable leukocyte extract therapy and, 495-96

Epinephrine atriopeptin secretion and, 32
inositol phosphate release and, 85

Epoxide hydrolases embryonic defense and, 181-82

Erythromycin N-demethylation cytochrome P-450 enzymes and, 247

Estradiol-17 β cytochrome P-450 enzymes and, 247
teratogenicity of, 175

Estrogens androgen conversion to, 253
dyslipidemias and, 280-81
kallikrein gene expression and, 348

Ethanol cytochrome P-450 enzymes and, 250
teratogenicity of, 166, 175

17 α -Ethynodiol cytochrome P-450 enzymes and, 247

Evans, C. T., 253

Evans, J. P., 408

Excitatory amino acid receptors, 87-89, 365-91
cell growth and, 385
classification of, 367-81
developmental plasticity of, 382-84
excitotoxic actions of, 386-88
long-term potentiation of, 384-85

Excitatory amino acids transport sites of, 388-89

Exton, J. H., 90

F

Farsang, C., 524

Fatty acid oxidation

peroxisome proliferators and, 156

Fenofibrate hepatic peroxisome proliferation and, 151

Ferritin embryonic defense and, 182

Fibrates primary dyslipidemias and, 273-74

Fibrinolytic enzyme system biochemistry of, 325-29

Fijken, D. C., 332

Fisher, S. K., 84

Fish oils dyslipidemias and, 281-82

Flatman, J. A., 371

Fleisch, J. H., 123

Flint, O. P., 177

Flunitrazepam molecular properties of, 315-16

Fluocinolone acetonide concentration of biologic potency and, 59

Fog, T., 499

Fowler, C. J., 86

Foxworthy, P. S., 155

Freud, S., 520

Friedman, M. M., 3

Fudenberg, H. H., 475

Fungal diseases dialyzable leukocyte extract therapy and, 489-90

Furazolidone teratogenicity of, 171

Furness, J. B., 289, 292

Furosemide extracellular fluid volume and, 37

G

GABA benzodiazepine receptors and, 312

GABA receptor homeotypic modulation of, 17

Garbar, M., 95

Gavras, H., 354

Gemfibrozil hepatic peroxisome proliferation and, 151
lovastatin and, 279
primary dyslipidemias and, 273-74

Gene mutation, 196-200

Genotoxicity, 189-204
interpretation of, 203-4

Gibbons, I. L., 289

Gibson, J. E., 167

Giles, H., 224

Gill, D. L., 78

Gillette, J., 12

Glaser, U., 433

Glomerular filtration rate atriopeptin-induced natriuresis and, 36

Glucocorticoids alopecia totalis and, 66
atriopeptin gene expression and, 29
clinical potency of vasoconstrictor bioassay and, 56

Kallikrein gene expression and, 348

plasma levels of benzodiazepines and, 309
skin disease and, 59

topical psoriasis and, 65-66
stratum corneum and, 62

vehicles for, 55-59

Glucose tolerance nicotinic acid and, 275

Glutamate 2-amino-5-phosphonovalerate and, 88
neurotoxicity of, 459-60
phosphoinositide breakdown and, 87

Glutamate receptors ionotropic, 442-43
learning and memory and, 455-57

metabotropic, 443-44
modulation of, 441-61

neurodegenerative diseases and, 457-60

psychoses and, 460-61

signal transduction at, 442-44

Glutathione-S-transferase benzodiazepine receptors and, 316-17

leukotrienes and, 127

Glycine N-methyl-D-aspartate receptors and, 446

Gomperts, B. D., 90

Gonzales, R. A., 91

Gonzalez, F. J., 243, 244, 247

Gordon, G. B., 174, 174

Greenberger, P. A., 135

Greenwald, J. E., 23

Growth hormone release of benzodiazepines and, 309

GTP calcium release and, 78

GTP binding protein phospholipase C-coupled receptors and, 90-92

Guanethidine heart norepinephrine content and, 14

Guengerich, F. P., 241

H

Hahn, R. A., 135

Hales, B. F., 167, 168, 174, 179

Halushka, P. V., 213

Harris, R. A., 156

Harris, W. S., 265

Hatcher, W. H., 2

Heacock, A. M., 84

Heart rate
atrial stretch receptors and, 31

Heme
benzodiazepine receptors and, 313

Hemoglobin
atriopeptin and, 37

Heparin
exogenous
atriopeptin suppression and, 25

Hepatomegaly
peroxisome proliferators and, 150-51

Herpes simplex
dialyzable leukocyte extract therapy and, 493

Herpes simplex virus
acyclovir and, 111

Herzheimer, H., 133

Hess, R., 147

Hess, S. M., 14

Hexamethonium
muscarinic cholinergic receptors and, 83

Higashida, H., 89

High-density lipoprotein cholesterol
relative hypercholesterolemia and, 266

Higuchi, T., 56

Hinson, J., 12

Histamine
leukotrienes and, 126

HMG-CoA reductase inhibitors
primary dyslipidemias and, 278-79

Hobin, L., 72

Hokin, M., 72

Holroyde, M. C., 133

Homeostasis
hypothalamic-pituitary-adrenal axis and, 17-18

Huang, K. P., 77

Human immunodeficiency virus, 111

Huntington's disease
glutamate receptors and, 458
N-methyl-D-aspartate-like lesions in, 387

Hydrocortisone
concentration of
biologic potency and, 58-59

5-Hydroperoxyicosatetraenoic acid
leukotrienes and, 124

Hydroxy acids
skin disease and, 59

5-Hydroxyindole acetic acid
urinary content of
serotonin and, 12

17-Hydroxyprogesterone
cytochrome P-450 enzymes and, 254

Hypercholesterolemia
arteriosclerotic cardiovascular disease and, 265
gemfibrozil and, 274
hypertriglyceridemia and, 266
ion exchange resins and, 270
lovastatin and, 278-79
neomycin and, 280
nicotinic acid and, 275
probucol and, 272

Hyperlipidemia
fish oils and, 282
nicotinic acid and, 275
probucol and, 272

Hypertension
atriopeptin and, 38
kallikrein-kinin system and, 354-55

Hypertriglyceridemia
gemfibrozil and, 273-74
hypercholesterolemia and, 266

Hyperuricemia
nicotinic acid and, 275

Hyperolemia
atriopeptin secretion and, 31

Hypoglycemia
glutamate receptors and, 459

Hypolipidemics
cytochrome P-452 induction and, 150
hepatic peroxisome proliferation and, 147
hepatomegaly and, 150

Hypothalamic-pituitary-adrenal axis
homeostasis and, 17-18

Hypothyroidism
lipoprotein abnormalities and, 266

Hypoxia
atriopeptin release and, 32

I

Ibotenic acid
inositol phosphate formation and, 87

Illes, P., 524

Imipramine
antidepressant action of
serotonin and, 13
inositol lipid metabolism and, 83

Immune system
leukotrienes and, 123

Immunosuppressives
lovastatin and, 279

Indomethacin
leukotriene response and, 126

Inflammatory bowel disease
leukotrienes and, 123

Inositol phosphates
generation of, 72-76
metabolism of, 74-76
mode of action of, 76-79

Inositol triphosphate
intracellular calcium release and, 32

Insulin
dyslipidemias and, 280
kallikrein gene expression and, 348

Ion exchange resins
primary dyslipidemias and, 268-72

Iprindol
inositol lipid metabolism and, 83

Iproniazid
excitatory action of, 13

Irvine, R. F., 76, 79

Ischemia
bilateral hemispheric, 405-6
focal, 407-10
glutamate receptors and, 458-59
multiple, 410-11
unilateral hemispheric, 406-7

Isobutylmethylxanthine
leukotriene receptors and, 130

J

Jafferji, S. S., 81

Jain, R., 174

Jaiswal, A. K., 252

Janesco, G., 387

Janowsky, A., 82, 86

Joffy, A., 475

Johnson, A. J., 328

Johnson, B., 517

Johnson, J. W., 370

Jollow, D., 12

Juchau, M. R., 165

K

Kagimoto, M., 255

Kainate receptor properties of, 375-76

synaptic transmission at, 376-77

Kalant, O. J., 520

Kallikreins, 343-56

 molecular genetics and structure of, 344-49

 roles in disease, 353-56

Kamataki, T., 245

Kanigel, R., 8

Kaplan, J., 519

Karczmar, A. G., 1

Karpiak, S. E., 403

Katz, M., 55

Kellis, J. T. Jr., 253

Kendall, D. A., 82, 86

Ketamine

 N-methyl-D-aspartate receptor and, 372

Ketanserin

 serotonin inhibition and, 81

Kidney

 atriopeptin and, 36-37

 benzodiazepine receptors in, 310

Kidney disease

 lipoprotein abnormalities and, 266

Kinases

 kinin catabolism and, 353

Kinin receptors

 properties of, 350-52

Kinins, 343-56

 cellular and tissue responses to, 349-53

 molecular genetics and structure of, 344-49

 roles in disease, 353-56

Kitada, M., 245

Knight, A. G., 64

Krell, R. D., 127

Kumar, N. S., 147

L

Lader, M., 520

La Du, B., 9

Lalwani, N. D., 152

Laniado-Schwartzman, M., 251

Lapetina, E. G., 91

Lasker, J. M., 248, 250

Lawrence, H. S., 475, 476

Lazarow, P. B., 149

Leake, C., 523

Learning

 excitatory amino acid receptors and, 89

 glutamate receptors and, 455-57

Learning process

Leff, P., 224

Leishmaniasis

dialyzable leukocyte extract

 therapy and, 492-93

Lepromatous leprosy

 dialyzable leukocyte extract

 therapy and, 490-92

Lesser, P. G., 490

Leukemic cells

 phospholipase C activation in, 91

Leukotriene receptor antagonists, 123-38

 characteristics of, 129-33

 pharmacologic evaluation of, 135-37

 structural types of, 127-29

Leukotriene receptors, 226-29

 purification and biophysical properties of, 228-29

 radioligand-binding studies of, 227-28

 second messenger systems for, 226-27

Leukotrienes

 airway smooth muscle and, 125-27

 formation of, 123-24

 human pharmacology of, 133-35

 pharmacologic effects of, 123

Leupeptin

 proatriopeptin-processing enzyme and, 33

Levinthal, C. F., 521

Lewtas, J., 415

Lieberthal, W., 355

Lithium

 phosphoinositide metabolism and, 96-97

Litosch, I., 90

Liver

 drug-metabolizing enzyme system of, 9

 peroxisome proliferation in, 145-57

Lock, E. A., 145

Lodge, D., 372

Loewi, O., 3

Louie, E., 502

Lovastatin

 primary dyslipidemias and, 278-79

Low-density lipoprotein cholesterol

 arteriosclerotic cardiovascular disease and, 265-66

Lübbert, H., 82

Lucas, D. R., 386

Lundberg, J. M., 292

Luteinizing hormone

 release of

 atriopeptin and, 26

 benzodiazepines and, 309

Lymphocytes

 benzodiazepines and, 315

M

MacDonald, B. R., 135

MacDonald, J. F., 371, 375

Macrophages

 benzodiazepines and, 315

Magnesium

 N-methyl-D-aspartate receptors and, 444-45

Maier, H., 520

Mais, D. E., 213

Majerus, P. W., 76

Malaria

 atabrine therapy and, 4

Malignant diseases

 dialyzable leukocyte extract therapy and, 496

Malathion

 skin disease and, 59

Manic depression

 lithium and, 96

Manson, J. M., 176

Margolius, H. S., 343

Marone, G., 135

Marshall, K., 4

Mast cells

 phospholipase C activation in, 91

Matsuo, H., 26, 39

Mateson, K. J., 254

Mayer, M. L., 372

Mayeux, P. R., 213

Lithium

 phosphoinositide metabolism and, 96-97

Mccarty, W. R., 328

McKinlay, M. A., 111

Mecamylamine

 muscarinic cholinergic receptors and, 83

Melanogenesis

 benzodiazepines and, 314

Melanoma

 dialyzable leukocyte extract therapy and, 496

Mellow, A., 82

Memory

 excitatory amino acid receptors and, 89

 glutamate receptors and, 455-57

Mendelson, C. R., 253

Mengoviruses

 structure of, 113

Mercuric chloride

 embryotoxic effects of, 180

Mesoporphyrin IX

 benzodiazepine receptors and, 313

Metastases

 dialyzable leukocyte extract therapy and, 497

Methadone, 523
 Methisazone
 pox virus replication and, 111-12
 Methoxamine
 atriopeptin-induced natriuresis and, 36
 inositol phosphate release and, 85
 Methoxyethanol
 teratogenicity of, 175
 Methylclophenapate
 hepatic peroxisome proliferation and, 149
 N-Methyl-D-aspartate-glycine receptor, 370-71
 N-Methyl-D-aspartate receptor, 87-89
 Alzheimer's disease and, 89
 developmental plasticity of, 382-84
 excitotoxicity of, 387
 heterogeneity of, 374-75
 ion channel of, 371-72
 blockade of, 372-73
 learning and memory and, 456-57
 long-term potentiation of, 384-85
 modulation of
 behavioral expression of, 452-55
 modulators of, 444-46
 recognition sites for, 446-51
 recognition site of, 370
 N-Methyl-D-aspartate receptor-ionophore complex, 368-75
 Meyer, T., 78
 Miadonna, A., 134
 Mianserin
 cortical serotonin receptor response and, 83
 Michell, R. H., 81
 Michener, M. L., 23
 Miller, J., 475
 Mineralocorticoids
 kallikrein gene expression and, 348
 Minneman, K. P., 86
 Mirkes, P. E., 168
 Misonidazole
 teratogenicity of, 171
 Mitchell, A. M., 145
 Mitchell, J., 12
 Mitochondria
 benzodiazepine receptors and, 311
 Mody, I., 375
 Molhave, L., 430, 432, 433
 Molowa, D. T., 246
 Monaghan, D. T., 87, 365
 Monoamine oxidase inhibitors
 action of
 norepinephrine levels and, 13
 Monocytes
 benzodiazepines and, 315
 Monooxygenases
 cytochrome P-450 mediated, 9
 Moor, R. M., 79
 Morinelli, T. A., 213
 Morris, J. L., 289
 Motivation
 N-methyl-D-aspartate receptors and, 453
 mRNA
 atriopeptin
 expression of, 26-27
 Muller, H. J., 198
 Muscarinic cholinergic receptors
 atropine and, 136
 phospholipase C and, 83-85
 Mutagenesis
 chemical, 196-200
 Muto, N., 253
 Myasthenia gravis
 dialyzable leukocyte extract therapy and, 499
 Mycobacterial diseases
 dialyzable leukocyte extract therapy and, 490-92
 Myocardial infarction
 pathophysiology of, 324-25
 thrombolytic therapy in, 323-36
 Myocardial ischemia
 leukotrienes and, 123
 N
 Nadelmann, E. A., 518
 NADPH
 drug-metabolizing enzyme system and, 9
 Nahorski, S. R., 82, 85, 97
 Nails
 drug penetration of, 64-65
 Nakashashi, Y., 355
 Nakaki, T., 81
 Nalorphine, 523
 Natriuresis
 atriopeptin-induced, 36-37
 Nebert, D. W., 176, 177
 Needleman, P., 23
 Neel, J. V., 200
 Neomycin
 phosphoinositide breakdown and, 91
 primary dyslipidemias and, 279-80
 Neurohybrid NCB-20 cells
 phospholipase C activation in, 91
 Neurologic diseases
 dialyzable leukocyte extract therapy and, 497-99
 Neurons
 chemically coded, 292-94
 Neurotensin
 phosphoinositide hydrolysis and, 89
 Neurotransmitters
 actions of
 diversity of, 296-300
 colocalization of, 289-301
 corelease of, 294-96
 Neutrophils
 phospholipase C activation in, 91
 Newall, D. R., 174
 Newhouse, J. P., 386
 Nicoletti, F., 86, 87
 Nicotinamide
 benzodiazepine receptors and, 312
 Nicotine
 major metabolite of, 425-26
 Nicotinic acid
 lovastatin and, 279
 primary dyslipidemias and, 274-78
 Nifedipine
 cytochrome P-450 enzymes and, 247
 Nifuroxime
 teratogenicity of, 171
 Niridazole
 teratogenicity of, 170-71
 Nishizuka, Y., 76, 77, 94
 Nitrofurantoin
 teratogenicity of, 171
 Nitrofurazone
 teratogenicity of, 171
 Nitroheterocycles
 teratogenicity of, 170-72
 2-Nitroimidazole
 teratogenicity of, 171
 Nitrosamines
 environmental tobacco smoke and, 426
 Norepinephrine
 atriopeptin secretion and, 32
 depletion of
 reserpine syndrome and, 13
 ganglionic
 acetylcholine and, 16
 heart content of
 adrenergic blockers and, 14
 inositol phosphate release and, 85
 leukotrienes and, 126
 monoamine oxidase inhibitors and, 13

Norethindrone acetate
dyslipidemias and, 281
Nowak, L., 372

O

Obesity
lipoprotein abnormalities and, 266

O'Brien, M. D., 408

Olney, J. W., 386, 388

Onychomycosis, 64

Opiate receptors, 522-23

Opioid peptides
regulatory role of, 524

Opiopeptins, 521-22

Oral contraceptives
dyslipidemias and, 280-81

Organomercurials
teratogenicity of, 166

Osteosarcoma
dialyzable leukocyte extract
therapy and, 496-97

Ostrenga, J., 55

Oxiconazole
nail penetration by, 64

Oxymetazoline
inositol phosphate release
and, 85

Oxyphenylbutazone
biotransformation of phenyl-
butazone to, 11

P

Painter, R. B., 195

Parquat
teratogenicity of, 175

Parasitic infections
dialyzable leukocyte extract
therapy and, 492-93

Parvoviruses
structure of, 113

Pasternak, G. W., 522, 523

Pelkonen, P., 251

Pemphigus vegetans
dialyzable leukocyte extract
therapy and, 495-96

Pentylenetetrazole
convulsions and, 314

Pepeu, G., 95

Peptidergic receptors
phosphoinositide hydrolysis
and, 89-90

Peptides
phosphoinositide hydrolysis
and, 89
See also specific type

Perchloroethylene
hepatic peroxisome proliferation and, 147

Peripheral nervous system
atriopeptin secretion and, 32

Permethrin
convulsions and, 314

Peroxidases
embryonic defense and, 181-
82

Peroxisomal enzymes
induction of, 148-49

Peroxisomes, 146-47
biogenesis of, 149
proliferation of, 147-51
induction of, 151-57

Pertussis toxin
phospholipase C activation
and, 91

Peterson, J. N., 408

Phenacetin
metabolism and distribution
of, 5

Phencyclidine
N-methyl-D-aspartate receptor
and, 372-73, 445-46

Phenobarbital
drug elimination rates and, 11
liver toxicity of carbon tet-
rachloride and, 12

Phenoxybenzamine
inositol lipid hydrolysis and,
85

Phentolamine
atriopeptin secretion and, 31

Phenylbutazone
biotransformation to ox-
yphenylbutazone, 11
duration of action of
plasma protein binding and,
11
metabolism and distribution
of, 5

Phenylephrine
inositol phosphate release
and, 85

plasma atriopeptin levels and,
31

Phentytoin
teratogenicity of, 175

Phillips, I. R., 252

Phorbol esters
phospholipase C-coupled re-
ceptors and, 94
protein kinase C and, 76

Phosphatidylethanolamine
benzodiazepine receptors and,
316

Phosphatidylinositol system
atriopeptin release and, 32

Phosphoinositide-coupled recep-
tors, 71-99

Phosphoinositides
hydrolysis of, 72-73

Phospholipase A₂
arachidonic acid and, 123

Phospholipase C
 α_1 -adrenergic receptors and,
85-87
excitatory amino acid recep-
tors and, 87-89
muscarnic cholinergic recep-
tors and, 83-85
phosphoinositide hydrolysis
and, 73-74
serotonergic receptors and,
81-83

Phospholipase C-coupled recep-
tors
characteristics of, 80-90
effectors and, 94-96
regulation of, 90-97

Phthalate ester plasticizers
hepatic peroxisome prolifera-
tion and, 147

Phystostigmine
thermoregulation and,
17

Picornaviruses
replication of
compounds inhibiting, 113-
16

Pirenzepine
muscarnic cholinergic recep-
tors and, 83-84

Plasmin
fibrinolytic enzyme system
and, 325-29

Plasminogen
fibrinolytic enzyme system
and, 325-29

Platelets
phospholipase C activation in,
91

Polioviruses
structure of, 113

Porcine brain natriuretic peptide,
26, 39-40

Porphyrins
benzodiazepine receptors and,
312-13

Postural hypotension
nicotinic acid and, 275

Potassium channel
phosphoinositide mechanism
and, 90

Potter, B., 12

Poulsen, B. J., 55

Pox viruses
methisazone and, 111-12

Prazosin
inositol phosphate release
and, 85

Probucol
primary dyslipidemias and,
272-73

Procainamide

metabolism and distribution of, 5

Procaine metabolism and distribution of, 5

Procarbazine teratogenicity of, 175

Progesterone cytochrome P-450 enzymes and, 247

Prolactin release of benzodiazepines and, 309

Propranolol atriopeptin secretion and, 31

Propylene glycol drug vehicles and, 55-56

Prostacyclin receptors, 217-21 purification of, 221 radioligand-binding studies of, 218-20 second messenger systems for, 217-18 subtypes of, 220

Prostaglandin D₂ receptors, 224-26 radioligand-binding studies of, 225-26 second messenger systems for, 225

Prostaglandin E receptors, 221-23 purification of, 223 radioligand-binding studies of, 222-23 second messenger systems for, 221-22

Prostaglandin F_{2α} receptors, 223-24 radioligand-binding studies of, 224 second messenger systems for, 224

Prostaglandin H₂ receptors, 213-17 purification and biophysical properties of, 217 radioligand-binding studies of, 216-17 second messenger systems for, 214-16

Prostaglandins derivation of, 123

Protein kinase C activation of diacylglycerol and, 32, 76-77 long-term potentiation of synaptic transmission and, 89

Proteratogens, 167-75

Protoporphyrin IX

benzodiazepine receptors and, 313

Psoralens skin disease and, 59

Psoriasis anthralin and, 62 leukotrienes and, 123 topical glucocorticoids and, 65-66

Psychosis glutamate receptors and, 460-61

Pulsinelli, W. A., 406

Putney, J. W. Jr., 79

Pyrethrins skin disease and, 59

Q

Quinidine cytochrome P-450 enzymes and, 247

Quinn, G. P., 10

Quinone oxidoreductases embryonic defense and, 181-82

Quirion, R., 41

Quisqualate receptor properties of, 375-76 synaptic transmission at, 376-77

R

Randerath, E., 426

Randerath, K., 191

Rasmussen, R. E., 195

Rasmussen, T., 408

Reddy, J. K., 147, 152

Regan, J. D., 191

Reid, W., 12

Renin release of atriopeptin and, 39

Renshaw, R. R., 3

Reserpine ACTH hypersecretion and, 17 pituitary-adrenocortical system and, 17 serotonin and, 12-13

Reserpine syndrome catecholamine depletion and, 13

Restriction fragment length polymorphisms kalikrein gene and, 347

Retinitis pigmentosa dialyzable leukocyte extract therapy and, 497-98

Retinoids sebaceous gland function and, 66 teratogenicity of, 166

Reuter, P., 519

Rhinovirus-14 structure of, 113

Rhinoviruses serotypes of, 113

Rhodin, J., 146

Richards, R. I., 344

Rifampicin S-mephenytoin-4-hydroxylation and, 250 teratogenicity of, 175

Rinkema, L. E., 130

Robertson, R. P., 222

Robinson, R. G., 408, 409

Robson, C. N., 180

Ronidazole teratogenicity of, 171

Rooney, T. A., 85

Rossmann, M. G., 111

Roth, B. L., 81

Rothman, S. M., 388

Rouiller, C., 146

Russel, W. L., 199

Ryan, P. B., 417

S

Saavedra, J. M., 41

Salicylic acid metabolism and distribution of, 5 skin disease and, 59

Salt appetite atriopeptin and, 42

Sanders-Bush, E., 82

Saper, C. B., 23

Scala, R. A., 422

Schaefer, H., 61, 64

Schizophrenia glutamate receptors and, 460-61

Schoemaker, H., 312

Scholtz, J. R., 59

Schwartz, J.-C., 95

Scopolamine muscarinic cholinergic receptors and, 83

Sebaceous glands retinoids and, 66

Second messengers generation of signal transduction at synapses and, 16

Seizures benzodiazepines and, 314

Selenium embryonic defense and, 181-82

Septic shock leukotrienes and, 123

Serotonin leukotrienes and, 126 reserpine and, 12-13

Serotonergic receptors
phosphoinositide turnover
and, 81-83

Serra, S. R., 354

Setlow, R. B., 191

Sexton, K., 417

Shannon, J. A., 3-5

Sherman, W. R., 96

Sherry, S., 330

Shimada, T., 248, 251

Shimizu, T., 225

Sickle building syndrome, 429-30

Single-chain urokinase-type plasminogen activator
pharmacology of, 334

Sladeczek, F., 87

Sliwka, A., 409

Slott, V. L., 168

Slow-reacting substance of anaphylaxis, 124
bronchospastic properties of, 133

Smith, H., 3

Smith, W. L., 221

Smooth endoplasmic reticulum
drug-metabolizing enzyme
system and, 9
hepatic peroxisome proliferation and, 149

Smooth muscle
airway
leukotrienes and, 125-27

Snyder, D. W., 123, 127

Snyder, J. S., 79

Snyder, S. H., 307

Sodium channel activators
inositol phosphate release
and, 92

Soter, N. A., 134

Stahl, M. L., 74

Steele, M., 4

Stewart, J. M., 350

Stockmann, P. T., 23

Stoughton, R. B., 55

Stratum corneum
percutaneous drug absorption
and, 61-63

Strauss, R. H., 517

Streb, H., 77

Streptokinase
myocardial infarction and,
324
pharmacology of, 329-31

Stresemann, E., 133

Stroke
animal studies in, 403-12
embolic, 410-11

Substance P
phosphoinositide hydrolysis
and, 89

Sulfinpyrazone
biotransformation of phenylbutazone to, 11

Sulfonamides
dosage adjustments with, 4

Sundt, T. M., 408

Sung, C. Y., 523

Superoxide dismutase
embryonic defense and, 181-82

Svoboda, D. J., 147

Synapses
signal transduction at
second messenger generation and, 16

T

Tagliafici, A., 403

Tamura, A., 408

Tan, L., 253

T cells
interactive
dialyzable leukocyte extract
therapy and, 486-87

Tennant, R., 324

Teratogenesis
chemical, 165-82

Tesh, J. M., 174

Testes
benzodiazepine receptors in,
309-10

Testosterone
conversion to estrogens, 253
cytochrome P-450 enzymes
and, 247

kallikrein gene expression
and, 347-48

teratogenicity of, 175

Tetradotoxin
inositol phosphate release
and, 92

Thalidomide
teratogenicity of, 166, 172-74

Theophylline
leukotriene receptors and, 130

Thermoregulation
catecholamines and, 17

Thiabendazole
nail penetration by, 64
skin disease and, 59

Thiazide diuretics
secondary dyslipidemias and,
266

Thiols
embryonic defense and, 181-82

Thiopental
clinical characteristics of
tissue distribution and, 11
metabolism and distribution
of, 5

Thomas, A. P., 78

Thrombolysis
myocardial infarction and,
323-36

Thromboxane A₂ receptors, 213-17
purification and biophysical
properties of, 217
radiooligand-binding studies of,
216-17
second messenger systems
for, 214-16

Thromboxanes
derivation of, 123

Thyrotropin-releasing hormone
phosphoinositide hydrolysis
and, 89

Thyroxine
dyslipidemias and, 281

Tinea capitis
antifungal therapy for, 66

Tissue plasminogen activator
fibrinolytic enzyme system
and, 326-29
pharmacology of, 332-34

Tobacco smoke
environmental, 422-27

Tocopherols
embryonic defense and, 181-82

Tolunay, H. E., 23

Tomato bushy stunt virus
structure of, 113

Transfer factor, 475-510
characteristics of, 479
immunotherapy with, 479-89
mechanisms of action of,
505-8
purification and characteriza-
tion of, 508-9
structure of, 502-5

Transferrin
embryonic defense and, 182

Tremorine
thermoregulation and, 17

Triamcinolone acetonide
biologic potency of
vehicle and, 57

Trichloroethylene
hepatic peroxisome prolifera-
tion and, 147

Tricyclic antidepressants
serotonin and, 13

2,2,4-Trimethylpentane
hepatic peroxisome prolifera-
tion and, 147

Tuberculosis vulgaris
dialyzable leukocyte extract
therapy and, 492

Tucker, S. S., 127

U

Udenfriend, S., 4, 5

Undecylic acid
nail penetration by, 64

536 SUBJECT INDEX

Uric acid
embryonic defense and, 181-82

Urokinase
fibrinolytic enzyme system and, 326-29

myocardial infarction and, 324

pharmacology of, 332

Uroporphyrin
benzodiazepine receptors and, 313

V

Valproic acid
hepatic CoA and, 156

Vancella zoster
dialyzable leukocyte extract therapy and, 493

Vasoactive intestinal peptide coexistence with acetylcholine, 95

Vasoconstrictor bioassay
glucocorticoid potency and, 56

Vasopressin
kallikrein gene expression and, 348

phosphoinositide hydrolysis and, 89

plasma atriopeptin levels and, 31

secretion of
atriopeptin and, 26, 41-42

Vavrek, R. J., 350

Veratridine
inositol phosphate release and, 92

Verma, A., 307

Very low-density lipoprotein dysbetalipoproteinemia and, 266

Vessel, E. S., 1

Vickers, C. F. H., 62

Vickery, L. E., 253

Viral infections
dialyzable leukocyte extract therapy and, 493-96

Vitamin A acid
skin disease and, 59

Vitamin K
bile acid-binding resins and, 271

Volatile organic chemicals
toxic effects of, 429-33

W

Wakade, C. G., 403

Walker, J. W., 82

Wallace, G. B., 3

Walters, K. A., 64

Watkins, J. C., 367, 386

Watts, J. W., 407

Way, E. L., 517

Weichman, B. M., 127

Weinberg, M. S., 355

Wells, P. G., 180

Welsch, F., 167

Westbrook, G. L., 372

White, P. C., 254

Wilhelm, O. G., 323

Williams, G. M., 189, 195

Williams, R. T., 10

Winsor, T., 64

Wroblewski, J. T., 441

X

Xenobiotics
hepatomegaly and, 150

Xu, J., 93

Y

Yang, B., 499

Yohimbine
inositol phosphate release and, 85

Yu, O.-F., 95

Z

Zaun, H., 59

Zhu, X.-Z., 84

Zinc
N-methyl-D-aspartate receptors and, 445

Zubrod, G., 4, 5

